U.S. Capital Wealth Advisors LLC Boosts Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

U.S. Capital Wealth Advisors LLC lifted its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 213.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,484 shares of the company's stock after purchasing an additional 10,551 shares during the period. U.S. Capital Wealth Advisors LLC's holdings in AstraZeneca were worth $1,138,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of AZN. Callan Capital LLC grew its position in AstraZeneca by 17.9% in the first quarter. Callan Capital LLC now owns 11,865 shares of the company's stock worth $872,000 after acquiring an additional 1,801 shares in the last quarter. TD Private Client Wealth LLC grew its position in AstraZeneca by 11.7% in the first quarter. TD Private Client Wealth LLC now owns 18,767 shares of the company's stock worth $1,379,000 after acquiring an additional 1,959 shares in the last quarter. Envestnet Asset Management Inc. grew its position in AstraZeneca by 5.5% in the first quarter. Envestnet Asset Management Inc. now owns 3,743,066 shares of the company's stock worth $275,115,000 after acquiring an additional 195,502 shares in the last quarter. Penserra Capital Management LLC grew its position in AstraZeneca by 7.6% in the first quarter. Penserra Capital Management LLC now owns 3,183 shares of the company's stock worth $233,000 after acquiring an additional 226 shares in the last quarter. Finally, Hendley & Co. Inc. grew its position in AstraZeneca by 56.1% in the first quarter. Hendley & Co. Inc. now owns 73,040 shares of the company's stock worth $5,368,000 after acquiring an additional 26,260 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company's stock.

AstraZeneca Trading Down 1.2%

Shares of NASDAQ AZN traded down $0.88 during midday trading on Friday, hitting $70.93. 1,441,555 shares of the company traded hands, compared to its average volume of 5,256,972. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $87.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90. The stock has a 50-day moving average price of $70.75 and a 200 day moving average price of $70.75. The firm has a market cap of $219.98 billion, a P/E ratio of 28.49, a P/E/G ratio of 1.31 and a beta of 0.37.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. The business had revenue of $13.59 billion for the quarter, compared to analysts' expectations of $13.71 billion. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The business's revenue was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.06 earnings per share. As a group, analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have weighed in on AZN. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research note on Wednesday. BNP Paribas began coverage on shares of AstraZeneca in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price target for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $89.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.